
Becton Dickinson & Company
Becton Dickinson and Co, formerly Becton Dickinson & Co is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company' s operations consist of three business segments: BD Medical, BD Diagnostics and BD Biosciences. On February 9, 2012, the Company acquired a 100% interest in KIESTRA Lab Automation BV. On August 24, 2012, the Company acquired a 100% interest in Sirigen Group Limited. On October 31, 2012, the Company sold its BD Biosciences -Discovery Labware unit. In December 2012, the Company acquired Safety Syringes, Inc. Effective March 12, 2013, the Company acquired Cato Software Solutions GmbH.
Profit margin stands at 8.0%.
Current Price
$154.51
-1.17%GoodMoat Value
$146.37
5.3% overvaluedBecton Dickinson & Company (BDX) Financial Statements
GoodMoat Analysis
Becton Dickinson exhibits a mixed financial profile for a value investor. While it generates a solid free cash flow yield and maintains a reasonable debt level, its growth is minimal and key profitability metrics like ROE are below typical quality thresholds.
Read full analysis
BDX Computed Insights
Income Statement
Balance Sheet
Cash Flow Statement
BDX Financial Statements & Data
Becton Dickinson & Company (BDX) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Becton Dickinson & Company's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $21.92B. Gross profit (TTM) is $10.10B. EBITDA is $5.05B. Earnings per share (EPS) is $5.82. The P/E ratio is 25.10. Market capitalization is $44.10B.
Free cash flow (FCF) is $2.67B. FCF growth rate is 1.98%. EPS growth CAGR is 1.98%. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Becton Dickinson & Company's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.